Hawkeye is focused on the development of population-scale testing for the early detection of cancer, neurodegenerative disease and inflammatory conditions.

Cancer is a growing problem among non-smokers and younger individuals who are typically excluded from national screening guidelines.

The Hawkeye team includes medical professionals with three-decades of success in oncology, medical practice and liquid biopsy clinical development.

Founded in 2019 and privately held, Hawkeye is based in Los Angeles and Ireland.